Group B Streptococcal Myocarditis

Worawut Roongsangmanoon* and Manasan Manavesunthornkiat

1 Department of Medicine, Srinakharinwirot University, Ongkharak Campus, Nakorn Nayok, Thailand
2 Department of Pathology, Srinakharinwirot University, Ongkharak Campus, Nakorn Nayok, Thailand

Abstract

Bacterial myocarditis is an uncommon form of infectious myocarditis. The definitive diagnosis requires histopathology with evidence of bacterial invasion. We report a case of group B streptococcal myocarditis secondary to septicemia with complete atrioventricular (AV) block and new left bundle branch block. The histopathology revealed patchy small foci of myocyte necrosis. The necrotic areas contained mixed inflammatory cell infiltration with a predominance of neutrophils. Necrosis in AV node was also observed. Gram stain in the necrotic area showed clusters of gram-positive cocci in agreement with the results of haemoculture. Bacterial myocarditis is a devastating complication of bacteraemia. This case highlights the ability of group B streptococci to cause life-threatening infections in adults without clear predisposing factors to serious infection. Bacterial myocarditis may progress quickly and be associated with a fatal outcome.

Keywords: Bacterial myocarditis; Group B Streptococcus; Electrocardiography; Atrioventricular

Introduction

The prevalence of bacterial myocarditis is not well established. The few published studies describe a post-mortem prevalence ranging from 0.2% to 1.5% [1]. The most common bacterial cause of myocarditis is Staphylococcus aureus, although infections with a broad range of bacterial pathogens have been described [1]. The definitive diagnosis requires histopathology-proven active myocarditis with evidence of bacterial invasion or positive tissue cultures. The management of bacterial myocarditis consists of aggressive and early antibiotic treatment, appropriate haemodynamic support, and treatment of the arrhythmias or complications.

Case Report

A 73-year-old woman presented with fever and back pain. The patient reportedly felt feverish and took over-the-counter medications for a few days, but the symptoms did not improve. She had a history of type 2 diabetes, hypertension, and dyslipidemia. Graves’ disease 10 years earlier had been treated with I-131 ablation. Medications included enalapril, metformin, simvastatin, levothyroxine, and omeprazole. The patient reportedly felt feverish and took over-the-counter medications for a few days, but the symptoms did not improve. She had a history of type 2 diabetes, hypertension, and dyslipidemia. Graves’ disease 10 years earlier had been treated with I-131 ablation. Medications included enalapril, metformin, simvastatin, levothyroxine, and omeprazole. The patient was ill looking, afebrile with a pulse rate of 65 beats per minute, a blood pressure of 100/60 mmHg, and a respiratory rate 20 breaths per minute. The first and second heart sounds were normal, without murmurs or rubs. There was no tenderness along the length of the spine and no tenderness at the costovertebral angle bilaterally. Systemic examination failed to reveal a focus of infection elsewhere and there was no neurological deficit.

An initial electrocardiography revealed normal sinus rhythm with incomplete right bundle branch block (Figure 1A). Reportedly, haemoglobin was 10.7 g/dl, total white blood cell count was 3,140 per cubic millimetre with 75% of neutrophils, and the platelet count was 84,000 per cubic millimetre. Serum creatinine was 3.1 mg/dl and potassium was 3.8 mmol/l. The creatine kinase level was 2,217 U/l and troponin T level was 1,392 ng/l. Blood cultures were drawn and an empiric treatment with ceftriaxone and intravenous fluid was started. Two hours later, she developed complete atrioventricular block and left bundle branch block with a heart rate of 50 (Figure 1B), severe acidosis, and hypoglycaemia. There was no urine output. Haemodialysis was commenced to correct the acidosis. During the subsequent hours her condition deteriorated rapidly. She died within 24 hours of admission in spite of cardiopulmonary resuscitation and high doses of vasopressors and inotropes.

Group B streptococci were found in the blood cultures taken on admission. Postmortem examination of the heart showed variable stenosis of the coronary arteries due to intimal fibrosis. The stenosis varied from 30-70% of the luminal area. However, no thrombosis was present.

Figure 1A: The initial electrocardiography revealed normal sinus rhythm with incomplete right bundle branch block.

B: Two-hours later, there was complete atrioventricular block and left bundle branch block with a heart rate of 50.

*Corresponding author: Worawut Roongsangmanoon, Department of Medicine, Srinakharinwirot University, Ongkharak Campus, Nakorn Nayok, Thailand, Tel: 66-37-395-085; E-mail: jwrorawut@yahoo.co.th

Received August 17, 2015; Accepted September 10, 2015; Published September 17, 2015

Citation: Roongsangmanoon W, Raveesunthornkiat M (2015) Group B Streptococcal Myocarditis. J Clin Case Rep 5: 593. doi:10.4172/2165-7920.1000593

Copyright: © 2015 Roongsangmanoon W, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The most common group B streptococcal infections in adults are bacteraemia, pneumonia, skin and soft tissue infections, bone and joint infections which usually occur in association with ageing, diabetes mellitus, malignancy, and HIV infection [3]. Cardiac infection due to Group B streptococci usually manifests as endocarditis, most commonly in immunocompromised patients [4]. Primary myocarditis associated with Group B streptococci is extremely rare. The usual pathological findings of streptococcal myocarditis are neutrophilic collections and microabscess in myocardium [5]. Other histopathological patterns reported in group B streptococcal myocarditis include diffuse myocarditis with suppurative pericarditis in which the myocardial infiltration consists mainly of lymphocytes and plasma cells with a small amount of neutrophils [6].

In this case, there were multiple microscopic foci of neutrophilic infiltration accompanied with necrosis of myocytes. The inflammation was randomly distributed and included atrioventricular node. Generally, neutrophilic infiltration with necrosis is also present in acute myocardial infarction. Moderate stenosis of coronary arteries was also identified in the patient. However, lack of thrombus or association with any vascular territories exclude an acute myocardial infarction diagnosis. In addition, collections of gram-positive cocci, intense active inflammation in the vessel wall without evidence of endocarditis suggest myocarditis caused by bacteraemia [7].

Clinical presentation of patients with bacterial myocarditis is dominated by sepsis or cardiac involvement including myocardial infarction, pericarditis, heart failure, atrioventricular block, ventricular tachycardia, or sudden death. Circulatory failure and shock can also be a prominent feature of acute bacterial myocarditis [8]. Differentiating sepsis-induced myocardial depression from bacterial myocarditis may be challenging. Both conditions share common features such as ventricular dysfunction and elevated serum troponin. A novel biomarker, ST2 (suppression of tumorigenicity 2) is a blood protein confirmed to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for interleukin-33. ST2 seems to confirm to act as a decoy receptor for inte...
References

1. Wasi F, Shuter J (2003) Primary bacterial infection of the myocardium. Front Biosci 5228-5231.
2. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, et al. (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology working group on myocardial and pericardial diseases. Eur Heart J 34: 2636-2648.
3. Skoff TH, Farley MM, Petit S, Craig AS, Schaffner W, et al. (2009) Increasing burden of invasive group B Streptococcal disease in nonpregnant adults, 1990–2007. Clin Infect Dis 49: 85-92.
4. Scully BE, Spriggs D, Neu HC (1987) Streptococcus agalactiae (group B) endocarditis: a description of twelve cases and review of the literature. Infection 15: 169-176.
5. Berry GJ, Atkin KA (2003) Pathology of human myocarditis: Myocarditis: from bench to bedside. Humana press, Totowa (NJ).
6. Bateman AC, Richards M, Pallett AP (1998) Fatal myocarditis associated with a Lancefield group B Streptococcus. J Infect 36: 354-355.
7. Burke AP, Tavora F (2011) Infections of the myocardium: Practical cardiovascular pathology. Lippincott Williams & Wilkins USA.
8. Haddad F, Berry G, Doyle R, Martineau P, Leung T, et al. (2007) Active Bacterial Myocarditis: A Case Report and Review of the Literature. J Heart Lung Transplant 26: 745-749.
9. Ciccone MM, Cortese F, Gesualdo M, Riccardi R, Nunzio DD, et al. (2013) A Novel Cardiac Bio-Marker: ST2: A Review. Molecules 18: 15314-15328.
10. Skouri HN, Dec GW, Friedrich MG, Cooper LT (2006) Noninvasive imaging in myocarditis. J Am Coll Cardiol 48: 2085-2093.